Quinolinic acid induced neurodegeneration in the striatum: A combined in vivo and in vitro analysis of receptor changes and microglia activation

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 4, 2008, Pages 704-715

  Moresco, R M ^a,b   Lavazza, T ^b   Belloli, S ^a   Lecchi, M ^d   Pezzola, A ^e   Todde, S ^a   Matarrese, M ^a   Carpinelli, A ^a   Turolla, E ^a   Zimarino, V ^b   Popoli, P ^e   Malgaroli, A ^b,c   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2A receptor; Dopamine D2 receptor; Emission tomography; Huntington's disease; Striatum

Indexed keywords

5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; CARBON 11; DOPAMINE 2 RECEPTOR; EXCITOTOXIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; QUINOLINIC ACID; RACLOPRIDE C 11; RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; CELL DENSITY; CELL LOSS; COGNITIVE DEFECT; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG RECEPTOR BINDING; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; ISOTOPE LABELING; LONGITUDINAL STUDY; MICROGLIA; MOTOR DYSFUNCTION; NERVE CELL; NERVE CONDUCTION; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RAT; RECEPTOR DENSITY; TREATMENT OUTCOME;

ANIMALS; CARBON RADIOISOTOPES; CORPUS STRIATUM; ISOQUINOLINES; KINETICS; MICROGLIA; NERVE DEGENERATION; QUINOLINIC ACID; RACLOPRIDE; RADIOISOTOPE DILUTION TECHNIQUE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, PURINERGIC P1; REFERENCE VALUES; STEREOTAXIC TECHNIQUES;

EID: 40949149575     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0651-7     Document Type: Article

References (49)

1. Walker FO. Huntington's disease. Lancet 2007;369:218-28.
2. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006;75:25-71.
3. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-59.
4. Scattoni ML, Valanzano A, Popoli P, Pezzola A, Reggio R, Calamandrei G. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease. Behav Brain Res 2004;152:375-83.
5. Alexi T, Venero JL, Hefti F. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. Neuroscience 1997;78:73-86.
6. Levivier M, Holemans S, Togasaki DM, Maloteaux JM, Brotchi J, Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol Res 1994;16:194-200.
7. Levivier M, Przedborski S. Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. Neurol Res 1998;20:46-56.
8. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995;287:215-7.
9. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001;60:161-72.
10. Ma L, Morton AJ, Nicholson LF. Microglia density decreases with age in a mouse model of Huntington's disease. Glia 2003;43:274-80.
11. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123(Pt 11):2321-37.
12. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 2006;23:190-7.
13. Saito K, Heyes MP. Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis. Adv Exp Med Biol 1996;398:485-92.
14. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996;320(Pt 2):595-7.
15. Heyes MP. The kynurenine pathway and neurologic disease. Therapeutic strategies. Adv Exp Med Biol 1996;398:125-9.
16. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005;31:395-404.
17. Guillemin GJ, Meininger V, Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:166-76.
18. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005;49:15-23.
19. Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005;5:1053-75.
20. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006;27:310-6.
21. Belloli S, Moresco RM, Matarrese M, Biella G, Sanvito F, Simonelli P, et al. Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo pet imaging of neurodegeneration. Neurochem Int 2004;44:433-40.
22. 11C]SCH442416. Eur J Nucl Med Mol Imaging 2005;32:405-13.
23. Araujo DM, Cherry SR, Tatsukawa KJ, Toyokuni T, Kornblum HI. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Exp Neurol 2000;166:287-97.
24. Topper R, Gehrmann J, Schwarz M, Block F, Noth J, Kreutzberg GW. Remote microglial activation in the quinolinic acid model of Huntington's disease. Exp Neurol 1993;123:271-83.
25. 11C]methylated quinoline-2- carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors. J Med Chem 2001;44:579-85.
26. Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, et al. Fluvoxamine treatment and D(2) receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology 2007;32:197-205.
27. Todde S, Moresco RM, Simonelli P, Baraldi PG, Cacciari B, Spalluto G, et al. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. J Med Chem 2000;43:4359-62.
28. Gordon RJ, Tattersfield AS, Vazey EM, Kells AP, McGregor AL, Hughes SM, et al. Temporal profile of subventricular zone progenitor cell migration following quinolinic acid-induced striatal cell loss. Neuroscience 2007;146:1704-18.
29. Tattersfield AS, Croon RJ, Liu YW, Kells AP, Faull RL, Connor B. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neuroscience 2004;127:319-32.
30. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. New York: Academic; 1998.
31. Moresco RM, Loc'h C, Ottaviani M, Guibert B, Leviel V, Maziere M, et al. Effects of dopamine on the in vivo binding of dopamine D2 receptor radioligands in rat striatum. Nucl Med Biol 1999;26:91-8.
32. 11C]N-methylspiperone. Nucl Med Biol 2002;29:307-16.
33. 2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003;61:S12-8.
34. Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006;248:9-15.
35. 2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J Neurosci 2006;26:11371-8.
36. 2A-receptors. Neurosci Lett 1997;231:83-6.
37. Bal A, Bachelot T, Savasta M, Manier M, Verna JM, Benabid AL, et al. Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Brain Res Mol Brain Res 1994;23:204-12.
38. Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci U S A 2001;98:1964-9.
39. Nishino H, Kumazaki M, Fukuda A, Fujimoto I, Shimano Y, Hida H, et al. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci Res 1997;27:343-55.
40. Gebicke-Haerter PJ, Christoffel F, Timmer J, Northoff H, Berger M, Van Calker D. Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem Int 1996;29:37-42.
41. Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 2005;20:550-61.
42. Dihne M, Block F, Korr H, Topper R. Time course of glial proliferation and glial apoptosis following excitotoxic CNS injury. Brain Res 2001;902:178-89.
43. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006;80:308-22.
44. Rojas S, Martin A, Arranz MJ, Pareto D, Purroy J, Verdaguer E, et al. Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab 2007;27:1975-86.
45. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006;66:1638-43.
46. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57-69.
47. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 2004;17:455-61.
48. Stone TW. Inhibitors of the kynurenine pathway. Eur J Med Chem 2000;35:179-86.
49. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005;37:526-31.